Iritani, Soichi
Akuta, Norio
Kawamura, Yusuke
Kajiwara, Akira
Kasuya, Kayoko
Fujiyama, Shunichiro
Sezaki, Hitomi
Hosaka, Tetsuya
Kobayashi, Masahiro
Kobayashi, Mariko
Saito, Satoshi
Suzuki, Fumitaka
Arase, Yasuji
Ikeda, Kenji
Suzuki, Yoshiyuki
Kumada, Hiromitsu
Funding for this research was provided by:
the Japan Agency for Medical Research and Development (#JP20fk0210040 and #JP20fk0210073)
scientific research and development from the Ministry of Health, Labour and Welfare of Japan (#19HC1001)
Article History
Received: 2 September 2020
Accepted: 20 October 2020
First Online: 4 November 2020
Ethics approval and consent to participate
: The study was conducted in compliance with the International Conference on Harmonization guidelines for Good Clinical Practice (E6) and the 2013 Declaration of Helsinki. The protocol was approved by the institutional review board at Toranomon Hospital (number; 953). Written informed consent was provided by all patients prior to liver biopsy.
: Not Applicable.
: (1) Hiromitsu Kumada has received honoraria from MSD K.K., Gilead Sciences, AbbVie Inc., Eisai Co., Ltd, and Dainippon Sumitomo Pharma. (2) Norio Akuta has received honoraria from AbbVie Inc and Gilead Sciences. (3) Yasuji Arase has received honorarium from AbbVie Inc. (4) Masahiro Kobayashi has received honoraria from Eisai Co., Ltd. (5) Yusuke Kawamura has received honoraria from Eisai Co., Ltd. All other authors declare no competing interests.